{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:37:48Z","timestamp":1790807868651,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Factor H (FH), a member of the regulators-of-complement-activation (RCA) family of proteins, circulates in human plasma at concentrations of 180\u2013420 mg\/L where it controls the alternative pathway (AP) of complement in the fluid phase and on cell surfaces. When the regulatory function of FH is impaired, complement-mediated tissue injury and inflammation occur, leading to diseases such as atypical hemolytic uremic syndrome (a thrombotic microangiopathy or TMA), C3 glomerulopathy (C3G) and monoclonal gammopathy of renal significance (MGRS). A pathophysiological cause of compromised FH function is the development of autoantibodies to various domains of the FH protein. FH autoantibodies (FHAAs) are identified in 10.9% of patients with aHUS, 3.2% of patients with C3G, and rarely in patients with MGRS. The phenotypic variability of FHAA-mediated disease reflects both the complexity of FH and the epitope specificity of FHAA for select regions of the native protein. In this paper, we have characterized FHAA epitopes in a large cohort of patients diagnosed with TMA, C3G or MGRS. We explore the epitopes recognized by FHAAs in these diseases and the association of FHAAs with the genetic deletion of both copies of the <jats:italic>CFHR1<\/jats:italic> gene to show how these disease phenotypes are associated with this diverse spectrum of autoantibodies.<\/jats:p>","DOI":"10.3389\/fimmu.2020.607211","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:34:27Z","timestamp":1610019267000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Factor H Autoantibodies and Complement-Mediated Diseases"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuzhou","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolo","family":"Ghiringhelli Borsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dopler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella R.","family":"Pitcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda O.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.02.005","article-title":"The human complement factor H: functional roles, genetic variations and disease associations","volume":"41","author":"Rodriguez de Cordoba","year":"2004","journal-title":"Mol Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1755","article-title":"Structure of complement fragment C3b-factor H and implications for host protection by complement regulators","volume":"10","author":"Wu","year":"2009","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609073","article-title":"Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome","volume":"125","author":"Schramm","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2610","article-title":"A new map of glycosaminoglycan and C3b binding sites on factor H","volume":"181","author":"Schmidt","year":"2008","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1375297","article-title":"Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment","volume":"40","author":"Hofer","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200679","article-title":"Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome","volume":"189","author":"Blanc","year":"2012","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.05.009","article-title":"Factor H autoantibodies in membranoproliferative glomerulonephritis","volume":"52","author":"Goodship","year":"2012","journal-title":"Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-010-1446-9","article-title":"DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome","volume":"25","author":"Zipfel","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-313X.2011.01071.x","article-title":"Factor H and CFHR1 polymorphisms associated with atypical Haemolytic Uraemic Syndrome (aHUS) are differently expressed in Tunisian and in Caucasian populations","volume":"39","author":"Leban","year":"2012","journal-title":"Int J Immunogenet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.630871","article-title":"The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease","volume":"290","author":"Bhattacharjee","year":"2015","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.06.021","article-title":"Dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"56","author":"Sethi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 Nephritic Factors in C3 Glomerulopathy: A Case Series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015040385","article-title":"High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies","volume":"27","author":"Bu","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018070759","article-title":"Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome","volume":"29","author":"Bu","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900814200","article-title":"Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome","volume":"284","author":"Lehtinen","year":"2009","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00853","article-title":"Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS","volume":"10","author":"Valoti","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019050515","article-title":"CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"31","author":"Zipfel","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12916","article-title":"Characterization of genetic predisposition and autoantibody profile in atypical haemolytic-uraemic syndrome","volume":"154","author":"Gurjar","year":"2018","journal-title":"Immunology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ki.2011.152","article-title":"Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome","volume":"80","author":"Strobel","year":"2011","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molimm.2015.12.005","article-title":"Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome","volume":"70","author":"Nozal","year":"2016","journal-title":"Mol Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4074-4","article-title":"Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome","volume":"34","author":"Guo","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s12882-019-1640-3","article-title":"Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis","volume":"20","author":"Li","year":"2019","journal-title":"BMC Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801545","article-title":"Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1","volume":"202","author":"Dopler","year":"2019","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.607211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T11:34:30Z","timestamp":1610019270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.607211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2020.607211"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.607211","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"article-number":"607211"}}